Update: On June 25, 2024, the Minister of Health released a notice of intent and plan regarding health product shortages.
On June 5, 2023, the Minister of Health released a statement on drug and other health product shortages, providing an update on actions being taken aimed at minimizing shortages and their impacts.
As one action, Health Canada is conducting a 60-day consultation on improving access to drugs and other health products, which Health Canada states “will be used to develop solutions for Health Canada and others who have a role to play in helping prevent shortages”. The consultation will close on August 4, 2023.
As a further action, Health Canada established a new external Health Products Supply Chain Advisory Committee to share their expertise and provide advice on approaches to shortage prevention and management.
In addition, the Minister of Health will conduct “a series of roundtables with key stakeholders from June to September to discuss strategies and identify solutions to prevent and mitigate drug shortages”.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.Related Publications & Articles
-
Health Canada finalizes biosimilar guidance: comparative clinical efficacy studies not typically required
In Canada, biosimilar products are approved by way of a new drug submission, following Health Canada guidance first released in 2010 and significantly revised in 2016.Read More -
2026 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2026, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top storiesRead More -
Supreme Court of Canada: methods of medical treatment unpatentable, validity of Janssen’s paliperidone dosing regimen patent upheld
Today the Supreme Court of Canada released its decision in Pharmascience Inc v Janssen Inc, 2026 SCC 26 on the patentability of methods of medical treatment, dismissing Pharmascience’s appeal.Read More
